Arsia Therapeutics and Biogen are collaborating to improve treatment administration for hemophilia patients by enabling subcutaneous versions of treatments that are currently administered via intravenous infusion. As part of the collaboration, Biogen will utilize Arsia’s proprietary formulation technology. Arsia will receive an upfront payment and could be eligible to receive development, regulatory, launch and sales milestones of up to $100 million if multiple products are successfully commercialized. Arsia may also receive royalties on certain products arising from the collaboration.
Robert Langer, an institute professor at MIT and serial entrepreneur, is a founder of Arsia. Langer founded the company with fellow professor and entrepreneur Alexander Klibanov, Novartis professor of chemistry and bioengineering at MIT, and Alan Crane of Polaris Partners. “The foundational work Arsia technology allows will permit a wide range of effective treatments to reach patients that otherwise would not make it past development due to formulation limitations,” said Langer.
The deal is the largest announced to date leveraging Arsia’s work in the area of formulation development of protein pharmaceuticals and monoclonal antibodies.